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Generation of B and plasma cells involves several organs
with a necessary cell trafficking between them. A detailed
phenotypic characterization of four circulating B-cell subsets
(immature-, naïve-, memory- B-lymphocytes and plasma
cells) of 106 healthy adults was realized by multiparametric
flow cytometry. We show that CD10, CD27 and CD38 is the
minimal combination of subsetting markers allowing
unequivocal identification of immature (CD10+CD27-CD38+,
6±6 cells/mL), naïve (CD10-CD27-CD38-, 125±90 cells/mL),
memory B lymphocytes (CD10-CD27+CD38-, 58±42
cells/mL), and plasma cells (CD10-CD27++CD38++, 2.1±2.1
cells/mL) within circulating CD19+ cells. From these four sub-
sets, only memory B lymphocytes and plasma cells
decreased with age, both in relative and absolute counts.
Circulating plasma cells split into CD138– (57±12%) and
CD138+ (43±12%) cells, the latter displaying a more mature
phenotypic profile: absence of surface immunoglobulin,
lower CD45 positivity and higher amounts of cytoplasmic
immunoglobulin, CD38 and CD27. Unlike B lymphocytes,
both populations of plasma cells are KI-67+ and show weak
CXCR4 expression.
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Introduction 
Human B-cell biology has been extensively documented.1
Circulating human B cells comprise two-thirds of CD27-
CD20+CD19+CD38- naïve B lymphocytes and one third of
CD27+CD20+CD19+CD38- memory B cells. Very low numbers
of plasma cells (2/mL) are found in peripheral blood of healthy
donors. Because of their low count, only few studies have
been devoted to characterizing their phenotype, most of them
dealing with newly generated plasma cells after in vivo immu-
nization.2 Steady-state circulating plasma cells lack CD20,
express CD19 and CD38high. It has been recently reported that
steady-state circulating plasma cells are mainly of mucosal ori-
gin, the majority of them secreting IgA (84%), expressing
CCR10 (56%) and β7 integrin (32%).3 Steady-state circulating
plasma cells are generally termed plasmablasts because only
half express CD138, a proteoglycan that is a hallmark of plas-
ma cells,4 while they are CD45+ and HLA-class II+.
Plasmablasts are generated in the lymph nodes, and induced
to circulate for a short period until they will reach a niche in
bone marrow, spleen, mucosa associated lymphoid tissues
(MALT) or lymph nodes.5 These niches will provide circulat-
ing early plasma cells with those factors required to survive
and to further differentiate into long-living mature plasma
cells.1 In murine bone marrow, plasma cell niche involves SDF-
1 producing cells and is shared with hematopoietic stem cells
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Figure 1. Phenotype of peripheral blood B-cell subsets, and focus on circulating plasma cells. (A) Distribution of immature (green), naïve
(pink), memory B lymphocytes (orange), and plasma cells (red), according to the expression of CD10, CD27 and CD38. (B) Cell phenotype
was analyzed by gating on CD19+CD20+CD38-/+ - naïve and memory - B lymphocytes (green), and CD19+CD20–CD38++ plasma cells (blue).
Histograms and dotplots show FACS labelings of cytoplasmic Ig (cyIg). The contribution of each Ig isotype is represented in the pie charts
and numbers are the mean percentages ± one SD for 13 healthy individuals. (C) CD20–CD38++CD138+ (a) and CD20–CD38++CD138– (b)
peripheral blood plasma cells were FACS sorted and stained with May-Grünwald-Giemsa (x1000 magnification). (D) Open histograms show
FACS labelings with indicated mAbs. Gray histograms display the corresponding negative control mAbs. Cell phenotype was analyzed by gat-
ing on CD19+CD20+ B lymphocytes, and both CD38++CD138– and CD38++CD138+ plasma cells. Data from one representative experiment is
shown. Numbers in panels indicate mean values of the staining indexes for each specific mAb used or the percentage of positive cells, deter-
mined on between 3 to 30 different healthy donors.
and pro-pre B cells.1 The rarity of this niche is a matter of
regulation of normal Ig production.6 In particular, new-
born plasmablasts, generated after in vivo Ag immuniza-
tion, have to compete with old plasma cells for binding to
a niche, inducing the old plasma cells to recirculate.7
Another minor population of circulating B cells which
accounts for 2-4% of all peripheral blood B cells has been
documented:8 transitional or immature B cells. These cells
have an immature phenotype (CD10+, CD24high, CD38high),
unmutated Ig genes and a reduced ability to be activated
in vitro.8,9 Notably, these immature B cells appear first in
peripheral blood after hematopoietic stem cell allograft8
and their frequency is highly increased in cord blood.8,9
Recently, additional heterogeneity has been reported for
human transitional B cells with a more differentiated stage
expressing ABCB1 transporter and intermediate density of
CD10 and CD38.10,11
There is a progressive defect to mount high affinity
humoral immune responses in elderly people.12 This
defect implies several mechanisms: i) a decrease in bone
marrow niches able to support B-cell generation and plas-
ma cell survival, due to the progressive replacement of
hematopoietic bone marrow by fat cells; ii) a defect in ger-
minal centers due to a decreased follicular dendritic cell
function and T-cell senescence; iii) a defect of B cells to
undergo Ig class switch recombination and somatic muta-
tion due to reduced E47 and AID gene expressions.13
In this study we have first characterized the above list-
ed populations of circulating B cells using multi-parameter
flow cytometry to define the best combination of markers
to identify them, and to study their fluctuation with age.
In addition, we have characterized in detail the activation
status and homing phenotype of steady-state circulating
plasma cells.
Design and Methods
Detailed methodologies are fully described in the Online
Supplementary Appendix. Briefly, peripheral blood from 106 adult
healthy donors was analyzed after informed consent was given.
Erythrocyte-lysed whole peripheral blood samples or mononu-
clear cells obtained by Ficoll-hypaque density gradient centrifuga-
tion were labeled with Abs conjugated with different fluo-
rochromes (Abs are listed in the Online Supplementary
Appendix). For intracellular staining of Ig or KI-67, cells were fixed
and permeabilized with the Cytofix/Cytoperm kit (BD
Biosciences). B-cell subpopulations were identified using a combi-
nation of 7-8 fluorochrome-conjugated Abs. The fluorescence was
acquired with a FACSCanto II or a FACSAria flow cytometer and
analyzed with the Infinicyt 1.3 software (Cytognos SL,
Salamanca, Spain). CD20-CD38++CD138- cells and CD20-
CD38++CD138+ cells were sorted with a FACSAria flow cytometer
to perform cytospins. Cells were stained with May-Grünwald-
Giemsa. Mean values and their SD, median and range were calcu-
lated for continuous variables with SPSS statistical software pack-
A. Caraux et al.
1018 haematologica | 2010; 95(6)
Figure 2. Age-related changes in circulating B-cell subsets. (A) Data plotted in each diagram represent correlation between the age of each
individual healthy donor and the percentage and absolute counts of total B cells (panels A and F, respectively), immature (panels B and G),
naïve (panels C and H), and memory (panels D and I) B lymphocytes, as well as plasma cells (panels E and J).
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age (SPSS 10.1 Inc., Chicago, IL). P values less than 0.05 were con-
sidered statistically significant.
Results and Discussion
Immunophenotypic characteristics of human peripheral
blood B-cell subsets 
Circulating B cells in a given individual are important
indicators of the state of B-cell production because gener-
ation of B lymphocytes and plasma cells involves sequen-
tial maturation steps in different organs and tissues14 and a
necessary cell traffic between these organs through
peripheral blood.15 Various strategies have been applied
for their identification and no study has comparatively
analyzed these four B-cell subsets in large cohorts of
healthy donors. Here, we show that four B-cell subsets
were systematically identified in peripheral blood of 106
healthy donors showing phenotypic profiles of immature
(CD10+CD19+CD20+CD27–CD38+)8, naïve (CD10–CD19+
CD20+CD27–CD38–)1, and memory (CD10–CD19+CD20+
CD27+CD38–) B lymphocytes,1 in addition to plasma cells
(CD10–CD19+CD20–CD27++CD38++).1 Principal compo-
nent analysis showed that CD10, CD27, and CD38 are
the minimal marker combination for unequivocal identifi-
cation of immature, naïve, and memory B lymphocytes, as
well as plasma cells among CD19+ B cells (Figure 1A).
Compared to naïve B lymphocytes, circulating immature
B lymphocytes, previously described as phenotypically
similar to transitional murine B cells,8 retain a phenotype
of late bone marrow B-cell precursors (i.e. CD5, CD10,
and CD38++) (Online Supplementary Figure S1), supporting
the hypothesis that they are immature B lymphocytes
leaving the bone marrow prior to full maturation.8
Transition from naïve to memory B lymphocytes was
characterized by increased CD24, CD25, CD27 and CD53
expression, and a downregulation of CD5 and CD23
(Online Supplementary Table S1). A fourth discrete CD19+
B-cell subset with higher light-scatter characteristics and a
plasma cell phenotype (CD20–, CD38++, CD27++ and cyto-
plasmic Ig (cyIg)+, with heterogeneous positivity for
CD138 (57±12% CD138– cells and 43±12% CD138+ cells)
was detected in all 106 healthy donors analyzed.
Fluctuation of peripheral blood B-cell subsets 
according to age
In our large cohort of 106 healthy donors, naïve and
memory B lymphocytes were highly represented, while
immature B lymphocytes and plasma cells were minor
populations (Table 1). No correlation was found between
age and percentages or absolute counts of total circulating
B cells, immature B lymphocytes or naïve B lymphocytes
(Figure 2). In contrast, statistically significant inverse cor-
relations were found between age and both the percent-
age and absolute count of circulating memory B lympho-
cytes (n=106; R2≤-0.22, P≤0.05) and plasma cells (n=106;
R2≤-0.27, P≤0.02). This also holds true when Ig heavy
chain isotype-specific subsets of plasma cells (IgG+, IgA+
and IgM+) and memory B lymphocytes (only for IgG+ and
IgM+) were considered separately (Online Supplementary
Figure S2A). Our results indicate that production of imma-
ture and naïve B-lymphocytes is not significantly affected
by aging, in contrast to previous suggestions by others.12,16
On the contrary, differentiation of naïve B lymphocytes
into memory B lymphocytes and then plasma cells, is
clearly reduced. These findings would confirm and extend
previous observations describing alterations on B cells
consisting of a more restricted diversity.12,16 In principle,
this could not be attributed to a lower ability for Ig class
switch since we have reported here decreased numbers of
both non-switched IgM+/IgD+, and switched IgG+ memo-
ry B lymphocytes with aging.13 This age-related decrease
in memory B lymphocyte counts could potentially be due
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to a lower exposure to new Ag (associated with a less-
exposed lifestyle) leading to a more restricted memory B-
cell repertoire or to an exhausted ability of memory B lym-
phocytes that have been triggered many folds along the
lifespan of elderly people, to generate expanded respons-
es. The age-associated decrease in the number of circulat-
ing IgA+, IgG+, or IgM+ plasma cells was even more pro-
nounced than that of memory B lymphocytes, suggesting
the occurrence of lower humoral response rates in the eld-
erly. In line with this hypothesis, no significant correlation
was found in our study between Ig heavy chain isotype-
specific circulating plasma cells and their serum antibody
counterpart (Online Supplementary Figure S2B).
Detailed characterization of circulating CD138– and
CD138+plasma cells
FACS-sorted CD138–CD20–CD38++ and CD138+CD20–
CD38++ cells showed a typical plasma cell cytology with
no obvious morphological differences (Figure 1C). CD138+
plasma cells showed a greater staining index (SI) than
CD138– plasma cells for CD38 (22% increased SI; n=30,
P=0.002), cyIg κ and λ light chains (47% and 98%
increased SI, respectively; n=6, P=0.04), CD27 (117%
increased SI, n=12, P=0.0004), and a lower SI for CD45
(24% decreased SI; n=6, P=0.004) (Figure 1D). In addition,
CD138– plasma cells, unlike CD138+ plasma cells,
expressed weakly CD20 and sIg (Figure 1D) consisting of
sIgA+ (49±12%), sIgG+(13±11%), sIgM+sIgD–(18±12%)
and sIgM–sIgD+ (5±17%), but no sIgM+/sIgD+ plasma cells.
After cell permeabilization, 42±14% cyIgA+, 31±14%
cyIgG+ and 26±10% cyIgM+ plasma cells were identified
(Figure 1B), with no differences in isotype distribution
between CD138– and CD138+ plasma cells. The lower fre-
quency of sIgG+ vs. cyIgG+ plasma cells might be due to
the weak sIg expression that is not optimally detected by
the anti-IgG Ab or a more mature sIgG– phenotype of cir-
culating plasma cells. Although HLA-class II (including
HLA-DR) expression was heterogeneous and lower in cir-
culating plasma cells compared to peripheral blood B lym-
phocytes (n=6, P≤0.001), a similar expression was found
in CD138– vs. CD138+ plasma cells (Figure 1D). Unlike B
lymphocytes, both CD138– and CD138+ plasma cells were
CD43+. Regarding homing receptors, both CD138– and
CD138+ plasma cells showed higher levels of α4 integrin
(n=6, P≤0.03), heterogeneously lower amounts of CXCR4
(18.8±9.1% and 11.0±6.1%, respectively; n=6, P≤0.0001),
and negativity for CD200 as compared to B lymphocytes,
which were constantly positive for the latter two markers
(Figure 1D). CD138+ plasma cells expressed lower levels of
β7 integrin (n=6, P=0.02) and L-selectin/CD62L (n=5,
P=0.03) and higher levels of β1 integrin (n=6, P=0.008)
than B lymphocytes (Figure 1D). CCR10 was not
expressed by circulating B lymphocytes while it was
weakly positive on both CD138– and CD138+ plasma cells.
Of note, high CCR10 expression was detected on the XG-
1 and XG-10 myeloma cell lines or on in vitro generated
plasmablasts with the same anti-CCR10 mAb reagent
(Online Supplementary Figure S3).17,18 No significant differ-
ence in CCR10 expression was found among plasma cell
subsets showing different Ig heavy chain isotypes (data not
shown). Furthermore, both circulating B lymphocytes and
CD138– and CD138+ plasma cells were constantly nega-
tive for VCAM1 (CD106), α5 integrin (CD49e), LFA-3
(CD58), and CD70, as well as for the CD56 and CD117
markers, which are aberrantly expressed by malignant
plasma cells (data not shown).19 Based on KI-67 antibody,
circulating B lymphocytes were quiescent (1.2±0.8% KI-
67+ cells) while circulating CD138– or CD138+ plasma cells
displayed a highly-activated phenotype with 66.8±29.7%
and 76.2±12.5% KI-67+ cells, respectively (n=11;
P≤0.00003, Figure 1D). Further staining with annexin-V
showed that both CD138– and CD138+ plasma cells were
fully viable with only 6.8% and 7.7% of these cell subsets
showing annexin-V+ staining, respectively.
Mei et al. have suggested that the great majority of cir-
culating plasma cells could have a mucosa origin, because
they secrete mainly IgA (84%) and partially express
CCR10.3,6 We did not confirm these results, since only 40-
50% of all peripheral blood plasma cells were IgA+ and
CCR10 was very weakly expressed by circulating plasma
cells. This discrepancy is not due to a defect of the anti-
CCR10 mAb used (Online Supplementary Figure S3), but
could be due to a difference in the gating strategy to define
plasma cells and avoid contaminating cells. We used a gat-
ing on CD19+CD38high cells that comprise all and only
cyIgκ or cyIgλ positive cells. Mei et al. used two gating
strategies, either CD19+CD27high cells or cyIg+ cells.3
What is the origin and behavior of these circulating
plasma cells? Given mainly their HLA-DR and CD45
expressions, they are generally thought to be plas-
mablasts newly-generated in lymphoid organs. In agree-
ment with this hypothesis, the phenotype of these plas-
ma cells is close to that of in vitro generated
CD38++CD138– and CD38++CD138+ plasma cells which
we recently reported.18 But the possibility that a fraction
of circulating plasma cells could be bone marrow and/or
lymphoid-tissue-localized long-living plasma cells that
are induced to re-circulate from their niche should be
considered. HLA-DR and CD45 expressions are also
characteristics of long-living plasma cells, since a large
fraction of CD138+ bone marrow plasma cells expresses
HLA-class II (60%) or CD45 (65%).2,20 plasma cells,
which are believed to be long-living based on murine
models or by grafting human plasma cells in severe com-
bined immunodeficiency mice,6 are also present in the
spleen, MALT or lymph nodes. They are located in
APRIL-rich niches in the subepithelium,5 APRIL being an
important plasma cell survival factor.21 The phenotype of
these plasma cells is close to that of circulating CD38++
CD138– plasma cells (A Caraux et al., unpublished obser-
vations, 2010). In human spleen, these plasma cells are
located outside the follicles, express highly CD38, cyIg
(45% cyIgM, 40% cyIgG and 15% cyIgA), and, unlike
bone marrow plasma cells, weakly sIg, CD20 and did not
express CD138.1 They also express HLA-DR and CD45
and have mutated Ig genes. Such a recirculation of plas-
ma cells was hypothesized to explain the appearance of
circulating tetanus toxin-unrelated plasma cells, seven
days after immunization of healthy donors with the
toxin.7 If this mechanism occurs in case of tetanus toxin
immunization, it may also occur in steady-state condi-
tions with newly-generated circulating plasmablasts
competing with long-living plasma cells. The activation
status of the circulating plasma cells (KI-67+) could indi-
cate that they have been induced to recirculate by local
stimulation. A highly-regulated recirculation mechanism
has been demonstrated for murine hematopoietic stem
cells with circadian variations.22 These circulating
hematopoietic stem cells can home to non-hematopoiet-
ic tissues for a time to exert immune surveillance and
may enter back into the peripheral blood via lymphatics
and thoracic duct.23 As human bone marrow plasma cells
use a stromal niche that is similar to that used by
hematopoietic stem cells24 and as the count of circulating
CD34+ cells in steady-state conditions is similar to that of
circulating plasma cells in healthy donors, similar mech-
anisms could drive the circulation of hematopoietic stem
cells and plasma cells.
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